Is hydroxyethyl starch 130/0.4 safe?

Critical Care

Volumn 16, Issue 2, 2012, Pages

  Haase, Nicolai ^a   Perner, Anders ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH; HYPERTENSIVE FACTOR; HETASTARCH DERIVATIVE;

CRITICALLY ILL PATIENT; HUMAN; KIDNEY FAILURE; NOTE; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RESUSCITATION; RISK ASSESSMENT; SEPSIS; DRUG EFFECTS; FEMALE; FLUID THERAPY; KIDNEY; MALE; PHYSIOLOGY; SHOCK, SEPTIC;

FEMALE; FLUID THERAPY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; KIDNEY; MALE; SHOCK, SEPTIC;

EID: 84858080476     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11200     Document Type: Note

References (11)

1. Muller L, Jaber S, Molinari N, Favier L, Larché J, Motte G, Lazarovici S, Jacques L, Alonso S, Leone M, Constantin JM, Allaouchiche B, Suehs C, Lefrant JY, . AzuRéa Group Fluid management and risk factors for renal dysfunction in patients with severe sepsis and/or septic shock. Crit Care 2012, 16:R34. 10.1186/cc11213, 22377234, AzuRéa Group.
2. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K, . German Competence Network Sepsis (SepNet) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:125-139. 10.1056/NEJMoa070716, 18184958, German Competence Network Sepsis (SepNet).
3. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001, 357:911-916. 10.1016/S0140-6736(00)04211-2, 11289347.
4. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2011, 3:CD000567.
5. Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients with Severe Sepsis. , http://clinicaltrials.gov/ct2/show/NCT00464204
6. Hartog CS, Kohl M, Reinhart K. A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg 2011, 112:635-645. 10.1213/ANE.0b013e31820ad607, 21304149.
7. Crystalloid versus Hydroxyethyl Starch Trial (CHEST) Management Committee The Crystalloid versus Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality. Intensive Care Med 2011, 37:816-823. Crystalloid versus Hydroxyethyl Starch Trial (CHEST) Management Committee.
8. Perner A, Haase N, Wetterslev J, Aneman A, Tenhunen J, Guttormsen AB, Klemenzson G, Pott F, Bødker KD, Bådstøløkken PM, Bendtsen A, Søe-Jensen P, Tousi H, Bestle M, Pawlowicz M, Winding R, Bülow HH, Kancir C, Steensen M, Nielsen J, Fogh B, Madsen KR, Larsen NH, Carlsson M, Wiis J, Petersen JA, Iversen S, Schøidt O, Leivdal S, Berezowicz P, et al. Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S - Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial. Trials 2011, 12:24. 10.1186/1745-6215-12-24, 3040153, 21269526.
9. BaSES Trial: Basel Starch Evaluation in Sepsis. , http://clinicaltrials.gov/ct2/show/NCT00273728
10. Reinhart K, Perner A, Sprung CL, Jaeschke R, Schortgen F, Johan Groeneveld AB, Beale R, Hartog CS. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med 2012, 38:368-383. 10.1007/s00134-012-2472-9, 22323076.
11. Hilton AK, Bellomo R. A critique of fluid bolus resuscitation in severe sepsis. Crit Care 2012, 16:302. 10.1186/cc11154, 22277834.